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Hyperglycaemia in acute ischaemic stroke is traditionally associated with a worsened outcome. However,
it is unclear whether the impact of hyperglycaemia on stroke outcome is similar in lacunar and non-lacunar
infarctions.
The relation between serum glucose measured within 6h after stroke onset and functional outcome was inves-
tigated in 1375 ischaemic stroke patients who had been included in two placebo-controlled trials with lubeluzole.
The endpoint was a favourable outcome, defined as amodified Rankin Scale score 2 at 3 months.Classification
into lacunar (n¼168) and non-lacunar (n¼1207) strokes was based on clinical criteria according to the
Oxfordshire Community Stroke Project and findings on brain CTscan. Hyperglycaemia was defined as blood
glucose48mmol/l. A possible concentration-dependent effect of glucose on outcome was investigated in both
lacunar and non-lacunar stroke.
Multivariate analysis showed that hyperglycaemia was associated with decreased odds of a favourable outcome
in non-lacunar stroke (OR 0.60; 95% CI 0.41^0.88, P¼ 0.009), but with increased odds of a favourable outcome in
lacunar stroke (multivariate OR for glucose48mmol/l: 2.70; 95% CI 1.01^7.13, P¼ 0.048). In non-lacunar stroke,
there appeared to be a concentration^effect relation, as the odds of favourable outcome gradually decreased
with increasing glucose levels. In lacunar stroke, an association with favourable outcome was observed with
glucose levels48mmol/l, but this beneficial effect diminished with more severe hyperglycaemia412mmol/l.
In conclusion, hyperglycaemia has a detrimental effect in non-lacunar stroke, but moderate hyperglycaemia
may be beneficial in lacunar stroke.
Keywords: ischaemic stroke; hyperglycaemia; lacunar stroke; stroke subtype
Abbreviations: CGI¼ clinical global impression; CT¼ computed tomography; NSE¼neuron-specific enolase
Introduction
Several studies have identified hyperglycaemia as an inde-
pendent risk factor for death and more severe disability
following acute ischaemic stroke (Woo et al., 1988, 1990;
Kiers et al., 1992; Weir et al., 1997; Capes et al., 2001; Parsons
et al., 2002). Admission hyperglycaemia is common in acute
stroke patients and exists across the range of stroke subtypes
(Scott et al., 1999). There is a great deal of interest in
achieving glycaemic control in acute stroke patients (Walters
et al., 2006; Garg et al., 2006), and a large randomized
controlled trial, which employs the ‘Glucose–Potassium–
Insulin’ infusion, is ongoing (Major ongoing stroke trials,
2002). However, the question is whether treating hypergly-
caemia is warranted in all types of ischaemic stroke.
In animal models of reversible focal brain ischaemia,
hyperglycaemia consistently increased infarct size (Lin et al.,
1998; Anderson et al., 1999; Gisselsson et al., 1999).
Interestingly, however, in animals with end-artery infarcts
hyperglycaemia had a beneficial effect and decreased
infarct size (Ginsberg et al., 1987; Prado et al., 1988).
The investigators suggested that these animal data might
predict that lacunar infarctions would not be worsened by
hyperglycaemia. A small study found that hyperglycaemia
significantly increased serum levels of neuron-specific
enolase (NSE), which is a biochemical marker for neuronal
injury, in cortical strokes but not in lacunar strokes (Sulter
et al., 1998). Bruno and co-workers analysed the relation
between admission blood glucose (within 24 h of stroke
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onset) and clinical outcome in patients enrolled in the Trial
of ORG 10172 in Acute Stroke Treatment (TOAST),
a placebo-controlled, randomized, double-blind trial to
test the efficacy of a low-molecular weight heparinoid in
acute ischaemic stroke. They found that hyperglycaemia
worsened the outcome in non-lacunar stroke, but not in
lacunar stroke; in the placebo arm, hyperglycaemic patients
with lacunar stroke had a better outcome than normogly-
caemic patients (Bruno et al., 1999). This observation
has not been widely taken into account by the medical
community.
The aim of this study was to further explore a possible




Data were obtained from the United States and Canadian
Lubeluzole in Acute Ischaemic Stroke Study (LUB-INT-9)
(Grotta, 1997), and the European and Australian
Lubeluzole Ischaemic Stroke Study (LUB-INT-5) (Diener,
1998). Both studies were multicentre, randomized, placebo-
controlled trials that investigated efficacy and safety of
lubeluzole in acute ischaemic stroke and found that
lubeluzole given within 6 h after stroke onset did not
improve outcome at 3 months.
The target population was at least 18 years of age,
presenting with substantial neurological deficit within 6 h of
onset of an acute cerebral hemispheric ischaemic stroke.
They had to be alert to or arousable by minor stimulation,
and exhibit a significant motor deficit of the arm or leg.
Analyses
Blood was obtained within 6 h after stroke onset, and
glucose concentration was determined at the local study
centres. In accordance with previous studies hyperglycaemia
was defined as a blood glucose 48mmol/l (Weir et al.,
1997; Alvarez-Sabin et al., 2003). To investigate a possible
concentration-dependent effect, patients were stratified into
five groups on the basis of increasing glucose levels: 57,
7–8, 8–10, 10–12 and412mmol/l.
Patients were divided into lacunar and non-lacunar
stroke groups on the basis of clinical criteria according to
the Oxfordshire Community Stroke Project (typical clinical
lacunar syndrome and absence of evidence of cerebral
cortical dysfunction) (Bamford et al., 1991) and findings on
brain Computed Tomography (CT) scans performed at
baseline and between 4 and 7 days after admission. Stroke
severity was assessed with the National Institute of Health
Stroke Scale (NIHSS) in the LUB-INT-9 and with the
European Stroke Scale (ESS) in the LUB-INT-5. In both
studies, baseline stroke severity was also stratified into mild,
moderate or severe by a clinical global impression (CGI).
The modified Rankin Scale (mRS) was used to measure the
degree of residual disability at 3 months after stroke onset.
Favourable outcome was defined as mRS 2, which means
that a patient has no or only slight disability while
functionally independent (Uyttenboogaart et al., 2005).
Statistical methods
For univariate analyses, Mann–Whitney U or Pearson Chi
square tests were used, where appropriate. The relation
between initial stroke severity (CGI) and glucose levels was
assessed using Kruskal Wallis tests.
We performed logistic regression analysis to investigate
whether hyperglycaemia was an independent predictor for
functional outcome. We adjusted for possible confounders:
age, stroke severity (CGI), lubeluzole/placebo treatment and
diabetes. CGI was used instead of the stroke scales in order
to analyse the pooled data of both trials. Interaction terms
between glucose and CGI, and glucose and diabetes were
tested.
SPSS version 12 was used for statistical analyses. Statistical
significance was defined as a (two-sided) P-value50.05.
Results
Out of the 1446 patients included, 1375 had confirmed
ischaemic stroke, and these were the ones selected for this
study. There were 168 patients with lacunar stroke and
1207 patients with non-lacunar stroke. Baseline character-
istics of the patients are given in Table 1. There were
13 (8%) missing glucose values in the lacunar group and
107 (9%) in the non-lacunar group. At 3 months, 5 (3%)






Mean age, years (SD) 70 (12) 70 (13) 0.442
Male gender 102 (61) 653 (54) 0.107
Left hemisphere 56 (33) 558 (46) 0.002
CGI 50.001
Mild 26 (16) 34 (3)
Moderate 102 (61) 446 (37)
Severe 40 (24) 727 (60)
Mean blood
glucose, mmol/l (SD)
7.3 (3.3)y 7.9 (3.3)z 50.001
57mmol/l 99 (64) 573 (52)
7^8mmol/l 17 (11) 188 (17)
8^10mmol/l 18 (12) 156 (14)
10^12mmol/l 9 (6) 74 (8)
412mmol/l 12 (8) 109 (10)
Previous hypertension 109 (65) 659 (55) 0.012
Atrial fibrillation 21 (13) 369 (31) 50.001
Coronary artery disease 53 (32) 450 (37) 0.148
Diabetes 33 (20) 255 (21) 0.658
Note: Values are numbers (%). SD¼ standard deviation. P-values
calculated with Pearson 2-test, unless otherwise indicated.
y¼ 13 missing and z¼107 missing values. ¼Mann^Whitney
U test.
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and 31 (3%) mRS scores were missing in the lacunar and
non-lacunar group, respectively (Fig. 1).
The distribution of glucose levels was not significantly
different between the three categories of the CGI in lacunar
stroke; median values: 6.3mmol/l in mild, 6.2mmol/l
in moderate and 6.6mmol/l in severe stroke (P¼ 0.79).
Median glucose values in the non-lacunar group were
6.4mmol/l in mild, 6.8mmol/l in moderate and 6.9mmol/l
in severe stroke (P¼ 0.09).
In the univariate analysis (Table 2), hyperglycaemia
was significantly associated with worse outcome in the
non-lacunar group, and there was a trend towards better
outcome in the lacunar group. Less severe stroke and
younger age were significantly associated with a favourable
outcome in both groups. Diabetes was associated with an
unfavourable outcome in non-lacunar stroke.
The results of the multivariate analyses are presented in
Table 3. Hyperglycaemia, defined as blood glucose
48mmol/l, independently reduced the chance of a favour-
able outcome in non-lacunar stroke (OR 0.60; 95% CI
0.41–0.88, P¼ 0.009), but increased the chance of
a favourable outcome in lacunar stroke (2.70; 95% CI
1.01–7.13, P¼ 0.048) (Table 3).
Concentration-dependent effects of glucose levels
as assessed with multivariate analyses are shown in
Fig. 2. In the non-lacunar infarction group, there was a
concentration-dependent effect of higher glucose levels and
lower odds of favourable outcome. In the lacunar group,
the association with better outcome was mainly observed
for glucose levels between 8 and 12mmol/l, and diminished
with levels above 12mmol/l. There were no significant
interactions between hyperglycaemia and CGI or diabetes in
both the lacunar (P¼ 0.09; P¼ 0.32) and non-lacunar
groups (P¼ 0.79; P¼ 0.41). In all regression models, higher
age and more severe stroke were significant risk factors for
an unfavourable outcome, but diabetes and lubeluzole
treatment were not.
Discussion
This study confirms the detrimental effect of hyperglycae-
mia in non-lacunar stroke, and replicates the findings by
Bruno and co-workers that hyperglycaemia has no adverse
effect on functional outcome in lacunar stroke; instead
it may have a beneficial effect in this type of stroke
(Bruno et al., 1999). In our study, a beneficial effect of
hyperglycaemia on functional outcome in lacunar stroke
was independent of stroke severity, age, diabetes and
treatment with lubeluzole. In the TOAST study population,
a significant favourable effect on lacunar stroke was
demonstrated only in the placebo group (Bruno et al.,
1999). Although limited by low patient numbers, stratifica-
tion of patients on the basis of increasing glucose levels
suggested that the beneficial effect in lacunar stroke may be
confined to moderate hyperglycaemia, as it diminished with
glucose levels above 12mmol/l. In non-lacunar stroke, a
concentration-dependent effect was observed, in a sense
that increasing glucose levels decreased the chance of
favourable outcome.
These findings may have important consequences for the
treatment of hyperglycaemia in acute ischaemic stroke.
Currently, the Glucose Insulin in Stroke Trial (GIST) is
investigating whether glycaemic control in patients with
acute stroke improves outcome. Patients with acute stroke,
including lacunar infarctions, who are found to have raised
plasma glucose46.0mmol/l, are treated with a controlled
infusion of glucose/potassium/insulin to maintain glucose
at 4–7mmol/l (Major ongoing stroke trials, 2002). There is
interest in setting up additional acute stroke studies using
insulin infusion therapy (Garg et al., 2006; Walters et al.,
2006). It is important to define the stroke type because
treating hyperglycaemia to levels 57mmol/l may not be
necessary in lacunar infarctions, where, based on animal
experiments (Ginsberg et al., 1987; Prado et al., 1988),
it might adversely affect outcome. A standard symptom list
could be used for this purpose, which has been validated to
distinguish between different stroke subtypes in the acute
phase (Aerden et al., 2004).
Infarct size and outcome in cortical stroke is highly
dependent on collateral circulation and the fate of the
hypoperfused but still viable brain tissue, the penumbra.
By using perfusion-weighted and diffusion-weighted
magnetic resonance imaging, Parsons and colleagues
showed that hyperglycaemia in patients with acute ischae-
mic stroke had a detrimental effect on the penumbra and
led to an increased infarct size (Parsons et al., 2002).
Lacunar strokes are located in end-arteriolar vascular
territories, with no collateral supply. Studies with diffusion
weighted MRI and magnetic resonance spectroscopy suggest
that a metabolically compromised area surrounding
subcortical infarctions also exists (Labelle et al., 2001).
The detrimental effects of hyperglycaemia on the cortical
penumbra are not clearly understood, but can include
increasing tissue acidosis secondary to anaerobic glycolysis,
increased blood–brain barrier permeability, and vascular
changes (Dietrich et al., 1993; Anderson et al., 1999;
Martini and Kent, 2006). In the vasculature hyperglycaemia
causes a pro-vasoconstrictive, pro-thrombotic and
LUB-INT 5 / 9
1446 patients
1375 Ischaemic stroke 71 Haemorrhagic stroke
168 Lacunar stroke 1207 Non-lacunar stroke
13 missing glucose values





100 missing glucose values
 24 missing mRS values
7 missing glucose / mRS values 
Fig. 1 Selected patients for the multivariate analyses.
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Table 3 Multivariate analysis: predictors for favourable outcome
Lacunar Non-lacunar
OR 95% CI P OR 95% CI P
Hyperglycaemia 2.70 1.01^7.13 0.048 0.60 0.41^0.88 0.009
Age (years) 0.94y 0.91^0.97 50.001 0.95y 0.94^0.97 50.001
CGI 0.21z 0.10^0.42 50.001 0.23z 0.17^0.30 50.001
Diabetes 0.44 0.15^1.29 0.133 1.00 0.66^1.53 0.993
Lubeluzole 2.03 0.94^4.37 0.072 1.01 0.75^1.36 0.963
Note: Hyperglycaemia defined as blood glucose48mmol/l. Favourable outcome means a modified Rankin score of 0^2. yOdds ratio for
each year increase. zOdds ratio for comparing severe stroke with mild stroke.











Hyperglycaemia 24 (31)y 14 (19)z 1.9 (0.9^4.1) 65 (22)‰ 267 (34) 0.5 (0.4^0.7)
Male gender 51 (61) 49 (62) 0.9 (0.5^1.8) 174 (56) 448 (53) 1.1 (0.9^1.4)
Mean age, years (SD) 67 (14) 73 (9) ^ 65 (15) 73 (11) ^
CGI
Mild 18 (21) 6 (8) 10.0 (3.1^33)1 21 (6) 12 (1) 9.4 (4.5^19.7)1
Moderate 57 (68) 43 (54) 4.4 (1.9^10.3)2 197 (60) 236 (28) 4.5 (3.4^6.0)2
Severe 9 (11) 30 (38) 111 (34) 599 (71)
Left hemisphere 25 (30) 28 (35) 0.8 (0.4^1.5) 153 (47) 393 (46) 1.0 (0.8^1.3)
Diabetes 15 (18) 18 (23) 0.7 (0.3^1.6) 55 (17) 193 (23) 0.7 (0.5^0.9)
Hypertension 57 (68) 50 (63) 1.2 (0.6^2.3) 174 (53) 466 (55) 0.9 (0.7^1.2)
Lubeluzole 53 (63) 38 (48) 1.8 (1.0^3.4) 163 (50) 431 (51) 0.9 (0.7^1.2)
Note: Values are numbers (%). Favourable outcome means a modified Rankin score of 0^2. Hyperglycaemia defined as48mmol/l.
OR¼odds ratio (95% confidence intervals). CGI¼ clinical global impression of stroke severity. Mann^Whitney U test, P50.001.
y¼ 7 missing, z¼6 missing, ‰¼ 33 missing and ¼ 67 missing values. 1Odds ratio’s comparing mild with severe stroke. 2 Odds ratio’s
comparing moderate with severe stroke.
7-8 8-10 10-12 >120.1
1
10
ORs for favourable outcome
Glucose concentration (mmol/L)








Fig. 2 Relation between hyperglycaemia and functional outcome in lacunar and non-lacunar stroke. Adjusted for clinical global impression,
age, lubeluzole treatment and diabetes. Favourable outcome defined as mRS score 0^2 at 3 months.
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pro-inflammatory phenotype, which severely compro-
mises the microvasculature and collateral circulation and
enhances reperfusion injury (Martini and Kent, 2006).
Lacunar stroke associated with limb weakness, such as in
our study, is situated in white matter and damages axons
and glial cells. Lactate produced by astrocytes is an
important rescue source of energy for axons (Brown
et al., 2003) and perhaps also for oligodendrocytes
(Sanchez-Abarca et al., 2001). Therefore, it is tempting to
speculate that increased lactate production due to hyper-
glycaemia in lacunar ischaemia might fuel and salvage
axons and oligodendrocytes.
A strong point of this study is that all patients were well
documented, and that blood glucose was measured within
6 h of stroke onset. A limitation of the study is the relatively
low number of patients with lacunar strokes and the fact
that the study was not powered to detect effects of
hyperglycaemia.
In conclusion, our study suggests that moderate
hyperglycaemia in acute lacunar stroke may be beneficial.
This finding stresses the need to distinguish lacunar stroke
from cortical stroke in an early stage, especially when
therapies to normalize blood glucose are considered.
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